HeartSciences Inc
heartsciences.comWhat Do They Do?
Provides software for managing electrocardiogram data and devices that record heart signals and support computer-based analysis for healthcare providers.
10-K for FY2026, filed Jul 23, 2026We are a healthcare information technology company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of…View ↗
MyoVista Insights™ is classified as a Medical Device Data System (“MDDS”) and is exempt from the FDA 510(k) requirements. The platform is…View ↗
We have also developed the MyoVista® wavECG™ device, which provides conventional ECG functionality and is designed to host embedded AI-ECG…View ↗
How Do They Make Money?
The company expects fees for platform installation, software use, and algorithms offered through its marketplace; product-sale revenue is counted when an order ships.
10-K for FY2026, filed Jul 23, 2026
$4.3K
-
10-K for FY2026, filed Jul 23, 2026
$4.3K ↗
Who Are Their Customers?
Targets healthcare providers, from primary-care settings to large health systems; it reports platform deployments and commercial customer engagements at healthcare institutions.
10-K for FY2026, filed Jul 23, 2026
Do Revenues Turn Into Profits?
No. It lost $9.1M in FY2026.
10-K for FY2026, filed Jul 23, 2026
−$8.4MView ↗
10-K for FY2026, filed Jul 23, 2026
−$9.1MView ↗
10-K for FY2026, filed Jul 23, 2026
−$7.4MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Sep 14, 2026
−$3.2MView ↗
- ▲ +54% (Loss)
- vs −$2.1M in Q1 FY2026
-
Aug 7, 2026
Nasdaq notified HeartSciences of an equity-listing deficiency
Its shares remained listed while Nasdaq gave the company time to submit a plan to regain compliance.
Sources
8-K, filed Aug 7, 2026
On August 4, 2026, HeartSciences Inc. (the “Company” or “HeartSciences”) received a letter from the Listing Qualifications Department of…View ↗
Shrinking. Revenue fell 70% in 4 years, from $14.4K in FY2022 to $4.3K in FY2026, about 26% a year.
From device to platform
The older report centered on the MyoVista ECG device; the latest report centers on MyoVista Insights, with the wavECG device described as a complement.
10-K for FY2023, filed Jul 19, 2023 10-K for FY2026, filed Jul 23, 2026We are a medical technology company focused on applying innovative AI-based technology to an ECG, also known as an “EKG,” to expand and…View ↗
A different revenue model
The older report expected device sales paired with proprietary electrodes for each test; the latest report describes installation, software-use, and algorithm-marketplace fees.
10-K for FY2023, filed Jul 19, 2023 10-K for FY2026, filed Jul 23, 2026We are a medical technology company focused on applying innovative AI-based technology to an ECG, also known as an “EKG,” to expand and…View ↗
We expect to generate revenue from installation fees, software-as-a-service (“SaaS”) usage fees, and fees associated with AI-ECG algorithms…View ↗
Third-party algorithms added
The older report described a proprietary algorithm; the latest report describes a platform designed to host algorithms from HeartSciences and third-party developers.
10-K for FY2023, filed Jul 19, 2023 10-K for FY2026, filed Jul 23, 2026HeartSciences has designed the MyoVista to help address these limitations and extend the clinical capability of an ECG in detecting cardiac…View ↗
Who Do They Compete With?
Competes with GE Healthcare Technologies, Koninklijke Philips, Baxter International, Nihon Kohden, Anumana, Tempus Labs, and VIZ.ai
10-K for FY2026, filed Jul 23, 2026The medical device industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary…View ↗
Loading...
